OncLive TV

Celestia Higano, MD, professor of medicine and urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses PARP inhibitors in prostate cancer.

Sanjaya K. Satapathy, MD, associate professor, Transplant Hepatology Division of Surgery, Methodist University Hospital Transplant Institute, University of Tennessee Health Sciences Center, discusses preventing recurrence in orthotopic liver transplant recipients with hepatocellular carcinoma.

Joshua Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the significance of analyzing mutated genes in prostate cancer.

Bruno Sangro, MD, PhD, head of Hepatology Unit, Internal Medicine Department, Clinica Universidad de Navarra, discusses the safety profile of nivolumab (Opdivo) in advanced hepatocellular carcinoma (HCC).

Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses neoadjuvant chemotherapy versus surgery for patients with ovarian cancer.

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses managing toxicities associated with immunotherapy for patients with head and neck cancer.

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the immune-related toxicities for patients receiving checkpoint inhibitors for treatment of their renal cell carcinoma.

Anna Farago, MD, PhD, assistant, Medicine, Massachusetts General Hospital Cancer Center, and instructor, Medicine, at Harvard Medical School, discusses the combination of olarparib (Lynparza) and temozolomide (Temodar) for patients with small cell lung cancer (SCLC).

R. Kate Kelley, MD, associate professor, University of California, San Francisco, discusses biomarkers for immunotherapy in hepatocellular carcinoma.

Johanna C. Bendell, MD, director of GI Oncology Research at Sarah Cannon Research Institute, discusses the remaining questions researchers have with regorafenib (Stivarga) for patients with hepatocellular carcinoma (HCC).

Brian F. Chapin, MD, assistant professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses impact of active surveillance in the field of prostate cancer.

Dana M. Chase, MD, FACOG, an associate professor at Creighton University, University of Arizona College of Medicine, and gynecologist oncologist with Arizona Oncology, discusses the toxicity profiles and managing side effects of treatments for patients with recurrent ovarian cancer.

Jesper Andersen, PhD, associate professor, Biotech and Innovation Centre, University of Copenhagen, discusses the relationship between reduced organic cation transporter-1 (OCT1) and poor response to sorafenib (Nexavar) in hepatocellular carcinoma (HCC) and cholangiocarcinoma.

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the future of immunotherapy for patients with prostate cancer.

Dhanya K. Nambiar, PhD, Stanford University, discusses the next steps with targeting galectin-1 with radiation therapy and immune checkpoint inhibitors in patients with head and neck cancer.

Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses dose levels of cetuximab (Erbitux) in patients with head and neck cancer.

Sameer Parikh, MD, hematologist, Mayo Clinic, discusses first-line therapy choices for patients with chronic lymphocytic leukemia (CLL).

Grzegorz Nowakowski, MD, assistant professor of medicine, Mayo Clinic, discusses the evolving treatment paradigm of mantle cell lymphoma (MCL).

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses combining daratumumab (Darzalex) for patients with multiple myeloma.

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, discusses the increase in prevalence of early-onset colorectal cancer (CRC).

Christopher J. Kane, MD, professor of Surgery, chair, Department of Urology, UC San Diego Health, discusses the impact of genetic testing on patients with prostate cancer.

E. David Crawford, MD, professor of Radiation Oncology, University of Colorado School of Medicine, discusses ongoing trials regarding genetic testing for patients with prostate cancer.

Jamie E. Chaft, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses pivotal ongoing clinical trials in the landscape of EGFR-mutant non–small cell lung cancer (NSCLC).

Leena Gandhi, MD, PhD, director of the Thoracic Medical Oncology Program at NYU Langone School of Medicine, discusses sequencing challenges as well as emerging agents in the field of ALK-positive non–small cell lung cancer (NSCLC).

Daniel B. Costa, MD, PhD, MMSc, associate professor of medicine at Harvard Medical School, medical staff, Hematology/Oncology, medical director of the Cancer Clinical Trials Office, and Medical Center Thoracic Oncology Group Leader, of Beth Israel Deaconess Medical Center, discusses biomarkers beyond PD-L1 in development for immunotherapy in patients with non–small cell lung cancer (NSCLC).

Dana M. Chase, MD, FACOG, an associate professor at Creighton University, University of Arizona College of Medicine, and gynecologic oncologist with Arizona Oncology, discusses challenges facing gynecologic cancers.

Bradley J. Monk, MD, FACOG, FACS, professor, director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona, discusses immunotherapy for patients with gynecologic cancer.

Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses the potential with acalabrutinib and BGB-3111 for the treatment of patients with chronic lymphocytic leukemia (CLL).

Heather Dalton, MD, gynecologic oncologist, Arizona Oncology, discusses novel approaches emerging in the field of uterine cancer.

Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses the FDA approval of the PD-L1 inhibitor atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma as a frontline therapy or following progression occurring ≥12 months after neoadjuvant or adjuvant chemotherapy.